Liver Cancer News Banner

White House declares April 2024 as Cancer Prevention and Early Detection Month

This landmark announcement from the White House follows ongoing advocacy efforts, including a letter to President Joe Biden sent by Prevent Cancer Foundation, GLI, and 80 other advocacy groups to establish Cancer Prevention and Early Detection Month.

Routine cancer screening can detect cancer early and increases the likelihood of successful treatment. Given that the majority of primary liver cancers are from untreated chronic hepatitis B or C infection, it is great to see hepatitis B vaccination and hepatitis C testing recommended.

white house


Liver Cancer Care: Management of Hepatic Encephalopathy, Ascites, & Portal Hypertension

Please join us on April 18 for a liver cancer care webinar open to patients, caregivers, and health care professionals. Experts will discuss topics relevant to the care and treatment of liver cancer and its symptoms so that patients and providers alike can make informed care decisions.

Liver Cancer Care Webinar (2)


Bristol Myers Squibb’s Phase 3 CheckMate- 9DW Trial 

Bristol Myers Squibb announced successful results from its Phase 3 CheckMate -9DW trial, which evaluated Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for advanced hepatocellular carcinoma (HCC) patients who haven’t received prior systemic therapy. The trial met its primary endpoint of improved overall survival compared to the standard treatment choices sorafenib or lenvatinib. Additional treatment options for advanced liver cancer patients may be on the horizon.


NIH launches research network to evaluate emerging cancer screening technologies

The National Institutes of Health (NIH) has begun a clinical trials network to assess the potential benefits and harms of promising new cancer screening technologies and to determine the most efficient methods for integrating these innovations into standard care protocols. The NIH will use data from these trials to develop evidence-based guidelines for cancer screening to achieve wide adoption to reach diverse populations.

Blood Capture


Utilizing Interventional Radiology and Liver-directed Therapies

This video segment features a distinguished panel of physicians who discuss the impactful mechanisms underlying liver-directed therapies in HCC. Dr. Anne Covey remarks on the role of interventional radiology in cirrhosis, particularly in prolonging survival during inoperable, intermediate stages. Dr. Covey touches upon several treatment methods and their alignment with different stages of liver cancer and mentions promising advancements such as the use of drug-eluting beads.

liver image


Distinct tumor microenvironment characteristics in HBV-related HCC: Potential new treatment avenue

Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are leading causes of HCC, accounting for 60% to 70% of all cases. This study explains the distinctive microbial environment associated with viral HCC, particularly for hepatitis B-related HCC. The distinct profile results in a multitude of microorganisms that serve as identifiable biomarkers in hepatitis B-related HCC, which could facilitate easier detection and infiltration of cancer cells. Further research could investigate the manipulation of tumor microbiomes for HCC and other cancer treatment.


She beat a rare liver cancer – and now works with her father to find more cures

At 10 years old, Elana Simon started to show symptoms of fibrolamellar carcinoma (FLC), a rare form of liver cancer. After two years of misdiagnoses, Elana’s tumor was identified and successfully removed. Inspired by his daughter’s battle, Professor Sanford Simon redirected his research towards finding a cure for FLC. As she grew up, Elena helped collect samples and eventually joined the lab as she worked on her PhD. Their laboratory at Rockefeller University has achieved remarkable breakthroughs, including the fact that FLC stems from a singular environmental trigger rather than hereditary factors and that early removal of the tumor is crucial to prevent recurrence.



For more information about the Liver Cancers Council or to learn more about joining, please visit or email